JPRN-jRCT2080224608已完成3 期
A Phase III Comparison Study of NPF-08 in Patients Who Receive Colonoscopy
ihon Pharmaceutical Co., Ltd0 个研究点目标入组 602 人开始时间: 2019年3月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 602
研究概览
简要总结
In subjects undergoing colonoscopy, NPF-08 administered on the day of colonoscopy or in divided doses over 2 days was as effective as Mooviprep administered on the day of colonoscopy. As for the safety, there were no new concerns or clinically relevant events in any treatment groups.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Japanese men and women aged 20 years or older at obtaining the written informed consent.
- •2.Patients who require colonoscopy(except for emergency colonoscopy).
- •3.Patients who have the ability to consent and submit the written informed consent by themselves.
排除标准
- •1.Patients who have or are suspected to have gastrointestinal obstruction.
- •2.Patients who have or are suspected to have intestinal perforation.
- •3.Patients who have or are suspected to have toxic megacolon.
- •4.Patients who have or are suspected to have gastric evacuation disorder (gastroparesis).
- •5.Patients with intestinal stenosis or high-grade constipation (stool frequency of 2 or less in a week or who have used laxative on a daily basis).
- •6.Patients with vomiting reflex or in whom accidental ingestion may occur.
- •7.Patients with a history of gastrointestinal surgery (except for appendicectomy).
- •8.Patients who were decided as glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.
- •9.Patients with renal impairment (urea nitrogen: 25mg/dL or more, or creatinine: 2mg/dL or more)
- •10.Patients with hepatic dysfunction (total bilirubin: 3.0mg/dL or more, ALT: 100IU/L or more or AST: 100IU/L or more)
- •11.Patients who have undergone or require therapy due to high-grade cardiac disease (including angina pectoris or myocardial infarction)
- •12.Patients with high risk of arrhythmia (with a history or complications of QT prolongation, myocardial infarction, angina pectoris, cardiac failure or cardiomyopathy)
- •13.Patients with dehydration.
- •14.Patients who were diagnosed with active inflammatory bowel disease at screening period.
- •15.Inpatients due to the reasons other than endoscopy large bowel.
- •16.Patients who have undergone nutritional control using total parenteral nutrition or enteral nutrition.
- •17.Women who are or may be pregnant, lactating or wish to become pregnant during the trial period.
- •18.Patients with a history or high-risk of seizure.
- •19.Patients with a history of shock or hypersensitivity for the active ingredient of the investigational product.
- •20.Patients who have received the other investigational product within 4 months before the written informed consent or who are participating in the other clinical trials.
- •21.Patients in whom Investigator/Sub-Investigator decided not to be eligible for this trial.
研究者
相似试验
已完成
3 期
Study of NPF-08 in Patients Who Receive ColonoscopyPatients Who Receive ColonoscopyNCT03794310Nihon Pharmaceutical Co., Ltd632
已完成
2 期
Phase II study of NPO-13 during colonoscopyPatients who receive colonoscopyJPRN-jRCT2080224838ihon Pharmaceutical Co., Ltd158
已完成
2 期
Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total ColonoscopyBowel DiseaseNCT02265939Nihon Pharmaceutical Co., Ltd132
已完成
1 期
Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma MultiformeMalignant GliomaNCT00919737Nobelpharma24
尚未招募
3 期
A study to compare efficay of Inj. Phenylephrine versus Inj. Noradrenaline for treating low blood pressure during caesarean section.CTRI/2020/09/027551Dr Divakar S R